Kymera Investor Day Presentation Deck
UD
Rationally Designing Molecular Glues to Drug Historically
Undrugged/Unligandable Targets
To drug all genetically validated but undrugged and un-ligandable proteins through the discovery
of novel E3 ligases and small molecule glues
Undrugged Targets
No other technology can drug
Ligandable
Proteins
e.g.STAT3
Un-ligandable
Proteins
e.g. other transcription
Heterobifunctional
Degraders
factors
Molecular
Glues
KYMERA ©2021 KYMERA THERAPEUTICS, INC.
Our Approach:
We are NOT iterating on CRBN/IMID Scaffold
Identifying the best matched pairs between targets of interests and E3
ligases exploiting natural affinity augmented with small molecule glues
●
●
●
Established a platform that uses high content genetic-based screens,
structural insights, biological pathways deconvolution, degron discovery,
computational knowledge expansion
Multiple programs in discovery stage
Strategic partnerships with:
@
A-ALPHA BIO
W
UNIVERSITY of
WASHINGTON
KYMERA R&D DAY - December 16th, 2021
NYU
PAGE 96View entire presentation